On June 17, 2026, Humedix, a subsidiary of the Huons Group, made a major stride in the global aesthetics market by securing a patent registration decision from the Russian Patent Office for its next-generation complex filler, Valpien. This innovative product, which uniquely combines polynucleotide sodium (PN) and hyaluronic acid (HA), is now officially protected for both its composition and manufacturing method in Russia—a first among the twelve countries where Humedix has been pursuing patent recognition since 2022.
The announcement, reported by several Korean outlets including 주간한국, 뉴스1, 데일리팜, and Kpanews, marks a significant milestone for Humedix. The company had previously registered a domestic patent in 2022 for a filler manufacturing method containing DNA fractions (patent No. 10-2348467) and launched an international PCT (Patent Cooperation Treaty) application. While applications are pending in countries such as the United States, Russia has become the first to grant full patent registration for Valpien, signaling the product’s global potential.
The technology behind Valpien stands out in a crowded market. According to 데일리팜, the filler combines the superior biocompatibility and skin regeneration properties of PN with high-purity HA. What truly differentiates Valpien from existing PN fillers, however, is the inclusion of lidocaine—a local anesthetic that significantly reduces pain during procedures. This feature has not gone unnoticed by industry observers, who point to the growing demand for less invasive and more comfortable aesthetic treatments.
Humedix’s commitment to scientific rigor is evident in its clinical approach. In December 2025, the company completed a confirmatory clinical trial in South Korea involving 171 adults seeking improvement for crow’s feet wrinkles. The results, which demonstrated Valpien’s efficacy and safety, formed the basis for a product approval application submitted to the Korean Ministry of Food and Drug Safety in May 2026. Should the regulatory process proceed smoothly, Humedix plans to launch Valpien in the domestic market in the second half of 2026.
But the ambitions of Humedix extend far beyond South Korea. The Russian patent registration is not just a legal victory—it’s a strategic one. As Kpanews explains, Russia is recognized as a high-demand market for aesthetic procedures. The patent gives Humedix a crucial foothold for expanding into the broader Eurasian region, a market characterized by both rapid growth and increasing sophistication in consumer preferences.
CEO Kang Min-jong put it plainly in a statement on June 17, 2026: “Russia is a strategic market with high demand for aesthetic procedures. Based on the local patent registration, we will expand our market presence and broaden Valpien’s influence throughout Russia and Eurasia.”
This is not Humedix’s first foray into the Russian market. In September 2023, the company obtained product approval from the Russian Federal Service for Surveillance in Healthcare for its hyaluronic acid filler, Elavie Premier. Since then, Humedix has engaged in robust on- and offline marketing campaigns and implemented professional education programs for physicians across Russia. These initiatives have been aimed at cementing the company’s reputation as a “premium K-aesthetic” brand—a strategy that seems to be resonating with Russian consumers and medical professionals alike.
Industry analysts are taking note. As reported by 뉴스1, the successful patent registration of Valpien in Russia is expected to serve as a springboard for Humedix’s expansion into the entire Eurasian market. The company’s focus on securing intellectual property rights across multiple jurisdictions is seen as a proactive move to protect its technological edge and ensure long-term competitiveness.
The technical details of Valpien’s patented process are not incidental to its market appeal. By combining PN—known for its regenerative capabilities—with high-purity HA, and adding lidocaine, Humedix has created a filler that targets both skin rejuvenation and volumizing effects, while minimizing patient discomfort. This positions Valpien as part of a new generation of aesthetic products that promise not just cosmetic improvement, but also a more pleasant treatment experience for patients.
According to 주간한국, the clinical evidence gathered from the 171-person trial in South Korea has been pivotal in driving regulatory and commercial plans. The company’s application for product approval in Korea is viewed as a key step toward a broader rollout, with the possibility of rapid market entry later this year if approval is granted. Humedix’s strategy, as outlined in multiple reports, involves leveraging the Russian patent as both a shield and a lever: it protects the company’s unique technology from competitors while opening doors to lucrative partnerships and distribution deals in Eurasia.
The broader context is also worth considering. The global aesthetics market has seen a surge in demand for minimally invasive procedures, with fillers and injectables at the forefront. Consumers are increasingly seeking products that deliver natural-looking results with minimal downtime and discomfort. Humedix’s focus on combining cutting-edge materials science with patient-centered design reflects these evolving market trends.
Humedix’s achievements in Russia build on its growing track record in international markets. The earlier approval of Elavie Premier in Russia demonstrated the company’s ability to navigate complex regulatory environments and adapt its marketing strategies to local conditions. The ongoing investment in physician education and consumer outreach has helped to establish Humedix as a trusted name in premium aesthetic solutions.
Looking ahead, the company’s multi-pronged approach—combining robust intellectual property protection, rigorous clinical validation, and aggressive market development—positions it well for continued growth. As the Eurasian market opens up, Humedix is poised to capitalize on its first-mover advantage, with Valpien leading the charge.
In the ever-evolving world of aesthetic medicine, innovation and timing are everything. Humedix’s successful patent registration for Valpien in Russia is more than a legal milestone; it’s a testament to the company’s vision and determination to shape the future of beauty treatments—one market, and one breakthrough, at a time.